Kaida BioPharma was founded on the research principles and clinical evidence of KAD101 (Originally G129R), a growth hormone antagonist that has shown to induce programmed cell death (autophagy) in gynecologic tumors. Their collaboration with Dr. John Langenheim, professor at Thomas Jefferson University and Dr. Anil Sood at MD Anderson, who have published extensive research on G129R, has provided solutions we intend to bring to the clinic. Kaida is dedicated to providing a new hope for patients with treatment-resistant gynecological cancers. Their mission is to develop innovative therapies that target the specific needs of those patients, offering a medical treatment that can make a significant difference.